More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict

 
• By Kevin Grogan

An update on Bayer and Loxo's tissue-agnostic therapy for cancers with NTRK gene fusions has impressed, confirming the sustained durable effect of larotrectinib as it nears its action date for approval in the US.

Runner
Larotrectinib data driving drug to approval line • Source: Shutterstock

More from Anticancer

More from Therapy Areas